A day after President Donald Trump was considering lifting some of the quarantine mandates, healthcare leaders from the American Hospital Association, American Medical Association and American Nurses Association (ANA) released an open letter urging Americans to stay home.

Nurses and other healthcare providers on the front lines of the COVID-19 coronavirus pandemic are facing a shortage of personal protective equipment (PPE), including gloves, face shields, and N95 face masks. But grassroots efforts from citizens and companies are bringing PPE donations or funneling supplies from donors to medical facilities in response to pleas from the healthcare community.  

We are oncology nurses. We don’t shy away from hard discussions. We have the skills and tools to help others. But this pandemic is different. The COVID-19 coronavirus has changed the rules. It’s ushered in social distancing, limited contact, and induced a new level of panic. COVID-19 doesn’t care if you are a nurse or a patient. It is an equalizer between us all. 

On March 18, 2020, the U.S. Food and Drug Administration (FDA) issued a guidance for industry, investigators, and institutional review boards conducting clinical trials during the COVID-19 coronavirus pandemic in recognition that it may affect the conduct of clinical trials of medical products, including drugs, devices, and biologic products.

To address the COVID-19 coronavirus pandemic, on March 22, 2020, the U.S. Food and Drug Administration (FDA) issued a new guidance to sponsors and healthcare providers regarding certain Risk Evaluation and Mitigation Strategy (REMS)-required testing during this time.

The alarmingly quick spread of the COVID-19 coronavirus has put a strain on the U.S. healthcare system, including the availability of personal protective equipment and other safety resources. The speed at which the virus spreads requires an even swifter response from federal agencies, government officials, and public health experts to combat the disease. To cut the red tape and accelerate data collection, the Department of Health and Human Services (HHS) has used statutory authority under the Paperwork Reduction Act to survey Health Resources and Services Administration healthcare institutions to understand the current COVID-19 response, challenges institutions are facing, and ways to help.

On March 22, 2020, the U.S. Food and Drug Administration took action to increase the availability of ventilators, accessories, and other respiratory devices during the COVID-19 coronavirus pandemic to support patients with respiratory failure or difficulty breathing.

Alongside 11 other national nursing organizations, ONS Chief Executive Officer Brenda Nevidjon, MSN, RN, FAAN, participated in a meeting with President Trump, Vice President Pence, and other leaders from the administration at the White House on March 18, 2020, to discuss the nursing community’s needs and response to the COVID-19 novel coronavirus pandemic. Administrators from the Centers for Medicare and Medicaid Services, Centers for Disease Control and Prevention, and Coronavirus Task Force also attended.  

Oncology nurses were represented at a March 18, 2020, White House briefing with President Donald Trump, Vice President Mike Pence, and other members of the U.S. Coronavirus Task Force. Brenda Nevidjon, MSN, RN, FAAN, Oncology Nursing Society (ONS) chief executive officer, was invited to attend the meeting along with other nursing association leaders to discuss the health and safety of oncology nurses and the patients they care for during the COVID-19 novel coronavirus pandemic.

When the COVID-19 novel coronavirus pandemic hit the United States, in a matter of days clinicians were scrambling to find novel ways to screen, triage, and provide telehealth interventions to protect patients with chronic conditions who are especially vulnerable to COVID-19. As nurses, we are accustomed to helping patients in crisis acclimate to a changing environment, process large amounts of information, and have their psychosocial needs met.

Although many oncology nurses are well versed in donning and doffing (removal) of personal protective equipment (PPE) for administering hazardous drugs, but not infection control. Additionally, nursing colleagues in other specialties may not wear PPE as part of their daily practice. As the COVID-19 novel coronavirus pandemic changes that, oncology nurses should understand PPE use for infection control to promote safety for nurses and patients.   

The COVID-19 novel coronavirus pandemic is turning the world, inside and outside of the hospital, upside down. Not only are oncology nurses seeing high demands at work, but changes and restrictions are being instated at home as well.

Drug pricing is a top legislative issue for Congress, and amid rising COVID-19 concerns, health policy topics are more pressing than ever. On March 5, Senator Martha McSally (R-AZ) introduced the Lowering Prescription Drug Prices for America’s Seniors and Families Act of 2020, which would allow Medicare to negotiate prices after a drug’s patent expires as well as cap out-of-pocket prescription spending for seniors at $3,100 per year.

With the Centers for Disease Control and Prevention’s recommendations for practicing social distancing to slow the national risk of transmission of COVID-19 novel coronavirus, oncology nurses must take increased precautions with patients with cancer who are at increased risk for contracting or experiencing poorer outcomes from COVID-19. Patients require communication and education in these uncertain times.

During the COVID-19 novel coronavirus pandemic, patients might be fearful and uncertain if they should come to their clinic appointments. COVID-19 presents greater risks to older adults and people with comorbid diseases such as cancer and other chronic conditions, and patient concerns will likely increase the volume of phone calls into your clinics and telephone triage lines. Oncology nurses can use the opportunity to assess and educate patients.

Nurses and other healthcare providers are navigating a rapidly changing world during the COVID-19 novel coronavirus pandemic, and that includes answering patients’ questions about the disease. Anthony A. Fauci, MD, director of the U.S. National Institute of Allergy and Infectious Diseases, in a Clinical Conversations podcast, suggested a two-pronged approach to talking with patients about COVID-19.

As part of its focus to dismantle the 2010 healthcare law, the GOP repealed the Affordable Care Act individual mandate in 2017. Republican state attorneys general then challenged the law’s constitutionality in a series of lower court cases, and the most recent has been lingering in federal courts for more than a year. On March 2, the Supreme Court agreed to take up the issue, marking the third time the law will be heard at the highest court in the country.  

COVID-19 is a novel coronavirus (a large family of viruses that can cause cold-like illnesses) first identified in Wuhan, China, in December 2019. It is a respiratory illness and can be spread from person to person, possibly through respiratory droplets during close contact. The first case of COVID-19 in the United States was reported on January 21, 2020.

As the COVID-19 strain of the coronavirus disease spreads and affects medical supply manufacturing locations, concerns are mounting about the availability of personal protective equipment (PPE) for hazardous drug (HD) handling. Martha Polovich, PhD, RN and MiKaela M. Olsen, DNP, APRN-CNS, AOCNS®, FAAN, editors of ONS’s Safe Handling of Hazardous Drugs book, shared guidance for nurses facing supply challenges.